In addition, an ICOSLG inhibitor, AMG-557, has been in clinical trials for SLE and lupus arthritis, preliminarily showing safety and potential efficacy [45], with promising potential for RA. This evidence concerns the gene ICOSLG and systemic lupus erythematosus.